J. Yau

Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.

C. Rudin, Jason P. Burke, C. Bristow, 2020, Journal of medicinal chemistry.

A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.

Jeffrey W. Smith, J. Sacchettini, S. Sieber, 2017, Bioorganic & medicinal chemistry.

Point-of-Care Biomarker Assay for Rapid Multiplexed Detection of CRP and IP-10

K. Pettrone, Sunil Krishnan, M. Lochhead, 2023, medRxiv.